[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"LABORATORIOS INDUFAR\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100630814","safety-and-effectiveness-of-tirzepatide-in-patients-with-obesity-at-hospital-de-clnicas-paraguay-100630814",false,"NCT07492563","Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay","Effectiveness and Safety of Tirzepatide (t.g.) in Patients Treated at the Obesity Unit of the Department of Endocrinology of the Hospital de Clínicas, Faculty of Medical Sciences, UNA: Phase 4 Study","Inclusion Criteria:\n\n* Age ≥18 years\n* BMI ≥27 kg\u002Fm² with weight-related comorbidities OR BMI ≥35 kg\u002Fm²\n* Clinical indication for tirzepatide per treating physician\n* Paraguayan citizenship or permanent residence\n* Residence in Asunción or Metropolitan Area or possibility to assist to regular visits\n* Ability to attend visits for 12 months\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes or secondary diabetes\n* Known hypersensitivity to tirzepatide\n* Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome\n* Acute pancreatitis in last 12 months or chronic pancreatitis\n* Severe gastrointestinal disease\n* Bariatric surgery in last 12 months\n* Pregnancy or breastfeeding\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment (Child-Pugh B or C)\n* Unstable cardiovascular disease\n* Active cancer (except non-melanoma skin cancer completely resected)\n* Current use of other GLP-1 receptor agonists\n* Participation in another interventional trial within 30 days","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","This is a Phase 4 observational study evaluating the safety and effectiveness of tirzepatide (T.G.) manufactured by INDUFAR S.A. in 300 patients with obesity treated at the Obesity Unit of Hospital de Clínicas in Paraguay over 12 months. The primary objective is to assess the safety profile through monitoring adverse events. Secondary objectives include evaluating weight loss, metabolic parameters improvement, and treatment satisfaction in real-world clinical practice.",[24,25,26],"Obesity","Type 2 Diabetes Mellitus","Overweight With Comorbidities","NOT_YET_RECRUITING","2026-03-19",{"date":30,"type":31},"2026-03-25","ACTUAL",{"date":33,"type":20},"2026-03",{"date":35,"type":20},"2027-10",{"name":37,"class":38},"LABORATORIOS INDUFAR","INDUSTRY",""]